Britain and America have hammered out a significant bilateral deal that will maintain no import taxes on UK drug products going into the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has committed to raise spending on drugs through the National Health Service (NHS). This move secures that duties on these vital exports will stay at zero for a period of three years.
This deal comes after earlier threats to hike duties on branded pharmaceutical imports, with potential rates mentioned as high as double the cost.
"This deal between the Britain reinforces the global environment for cutting-edge drugs and establishes long-overdue equity to transatlantic drug exports," a statement declared.
Trade Importance
Drugs represent one of the UK's largest exports to the US, which is by far the biggest buyer for major British pharmaceutical firms.
Export figures indicate that in the 12 months to the end of September, the UK sold drugs totaling over eleven billion pounds to the US. This amount made up nearly one-fifth of total UK exports in that timeframe.
"This agreement protects jobs, stimulates capital expenditure and sets the stage for the UK to establish itself as a international leader for medical research," the Business and Trade Secretary remarked.
Specific UK Commitments
The agreement involves several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will lift the affordability limit at which it considers new medicines to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a goal to increase overall NHS spending on drugs from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage drug companies must pay back to the NHS to prevent overspending will be restricted at 15%. Previously, repayments exceeded 20%.
Broader Context
This agreement follows a protracted row between the sector and the British authorities over spending levels and regulatory access.
The disagreement were exacerbated by arguments that American consumers were charged significantly more for the same drugs than consumers in the other developed nations.
Recently, several significant manufacturing plans in the UK have been paused or abandoned, while major funding commitments have been announced toward projects in the United States.
The Science Minister acknowledged that the NHS had to invest a greater share on medicines, noting that its spending on drugs had declined as a proportion of its resources over the past decade.
